Drugs / CSC-DC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02178670 | Jun 2014 → Apr 2015 | ovarian cancer | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSC-DC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02178670 ↗ |
| Action | Deplete | “CTLs generated from peripheral blood mononuclear cells or splenocytes harvested from CSC-vaccinated hosts were capable of killing CSCs in vitro.” NCT02178670 ↗ |
| Modality | Vaccine | “generating CSC-loaded DC vaccines for clinical use” NCT02178670 ↗ |